John Oyler, CEO of BeOne Medicines, just cashed in a whopping $34.6 million by selling a major chunk of his shares over two days—July 20th and 21st—via a pre-planned strategy. Despite the big payout, he’s still deeply invested, holding millions of shares through LLCs and trusts. BeOne, a powerhouse in cancer drugs with a $34.2 billion market cap, continues to thrive thanks to blockbuster drugs like BRUKINSA and TEVIMBRA, generating over $5.7 billion in revenue last year. The stock’s been climbing 9% this year, and Oyler’s sale price averaged $315.28 per share—just ahead of the closing price. This move signals a major liquidity event, but not a loss of faith in BeOne’s oncology pipeline.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
